Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
I'm PortAI, I can summarize articles.
LifeSci Capital analyst Sam Slutsky has maintained a Hold rating on InflaRx’s IFRX stock due to uncertainties in trial results for INF904. The Phase 2a study showed some promising trends in hidradenitis suppurativa but had limitations, including a small sample size and lack of a placebo arm. For chronic spontaneous urticaria, the data did not indicate strong efficacy. The company plans to seek a partnership for further development, leading to a cautious outlook. Another report also reiterated a Hold rating with a $1.50 price target.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments